H. Lundbeck A/S
Company: H. Lundbeck A/S
Headquarters: Copenhagen, Denmark
Founded: 1915
Ticker: LUN.CO (OMX Copenhagen)
Employees: ~5,500
Revenue: ~14.5 billion DKK (2023)
Funding
- IPO: 1999 (CPH: LUN)
- Market Cap: ~$10B (2026)
- 2025 Revenue: DKK 25B
Overview
[H. Lundbeck A/S](/companies/lundbeck) (commonly known as Lundbeck) is a Danish multinational pharmaceutical company headquartered in Copenhagen, Denmark. Founded in 1915, Lundbeck has evolved into a focused neurosciences company dedicated to improving the lives of people with psychiatric and neurological disorders. The company is one of the few "pure-play" neuroscience companies globally, with a research portfolio concentrated entirely on brain diseases including [Alzheimer's disease, [Parkinson's disease, depression, and schizophrenia[@lundbeck2023].
Lundbeck operates in approximately 50 countries and has R&D facilities in Denmark, the United States, and the United Kingdom. The company's strategic focus on CNS (central nervous system) disorders positions it uniquely in an industry where most large pharmaceutical companies have reduced their neuroscience investments[@lundbeck].
Research Focus Areas
Lundbeck's research and development concentrates on several key therapeutic areas:
...H. Lundbeck A/S
Company: H. Lundbeck A/S
Headquarters: Copenhagen, Denmark
Founded: 1915
Ticker: LUN.CO (OMX Copenhagen)
Employees: ~5,500
Revenue: ~14.5 billion DKK (2023)
Funding
- IPO: 1999 (CPH: LUN)
- Market Cap: ~$10B (2026)
- 2025 Revenue: DKK 25B
Overview
[H. Lundbeck A/S](/companies/lundbeck) (commonly known as Lundbeck) is a Danish multinational pharmaceutical company headquartered in Copenhagen, Denmark. Founded in 1915, Lundbeck has evolved into a focused neurosciences company dedicated to improving the lives of people with psychiatric and neurological disorders. The company is one of the few "pure-play" neuroscience companies globally, with a research portfolio concentrated entirely on brain diseases including [Alzheimer's disease, [Parkinson's disease, depression, and schizophrenia[@lundbeck2023].
Lundbeck operates in approximately 50 countries and has R&D facilities in Denmark, the United States, and the United Kingdom. The company's strategic focus on CNS (central nervous system) disorders positions it uniquely in an industry where most large pharmaceutical companies have reduced their neuroscience investments[@lundbeck].
Research Focus Areas
Lundbeck's research and development concentrates on several key therapeutic areas:
| Area | Focus | Programs |
|------|-------|----------|
| [Alzheimer's disease](/diseases/alzheimers-disease) Disease | Amyloid/tau targeting, neuroinflammation | Lu AF20513 (vaccine), PDE4B inhibitors |
| [Parkinson's disease](/diseases/parkinsons-disease) Disease | [Alpha-synuclein](/proteins/alpha-synuclein), dopamine pathways | Lu AG06466, D1 agonists |
| Depression | Glutamate signaling, GABA modulation | Vortioxetine derivatives, FMR |
| Schizophrenia | Dopamine/serotonin modulation | Lu AF20071 |
Key Programs
Lu AF20513 (Amyloid Vaccine)
Lu AF20513 is an investigational [Alzheimer's disease vaccine designed to stimulate the immune system to produce antibodies against [amyloid-beta](/proteins/amyloid-beta) plaques:
- Mechanism: Multi-epitope DNA vaccine targeting amyloid-beta
- Status: Phase 1 completed
- Differentiation: Improved safety profile vs. earlier amyloid vaccines
PDE4B Inhibitors
Lundbeck is developing phosphodiesterase 4B (PDE4B) inhibitors for [Alzheimer's disease:
- Target: PDE4B enzyme involved in memory and neuroinflammation
- Rationale: Reduced neuroinflammation and improved cognitive function
- Status: Preclinical/Phase 1
Brain Shuttle Technology
Lundbeck has developed a bispecific antibody brain shuttle platform in partnership with Genentech (Roche) to overcome the [blood-brain barrier](/entities/blood-brain-barrier) challenge and enable delivery of therapeutic antibodies to CNS targets[@lundbeck2024].
Platform Mechanism:
The brain shuttle technology uses bispecific antibodies that:
One arm binds to the therapeutic target (e.g., amyloid, [tau](/proteins/tau), α-synuclein)
Second arm binds to transferrin receptor (TfR) for receptor-mediated transcytosis across the BBB
Utilizes native Fc-mediated recycling to enhance half-life
Achieves 5-10x increased CNS exposure compared to conventional antibodiesKey Programs:
| Product | Indication | Target | Development Stage | Notes |
|---------|------------|--------|-------------------|-------|
| Lu AG09222 | Migraine prevention | PACAP38/TfR | Phase 1 completed (2023) | First brain shuttle program |
| Lu AF20513 | Alzheimer's disease | Amyloid/TfR | Preclinical/Phase 1 | Bispecific anti-amyloid |
| Lu AF87908 | Alzheimer's disease | Tau/TfR | Phase 1 | Anti-tau bispecific |
Partnership with Genentech:
The collaboration with Genentech combines Lundbeck's neuroscience expertise with Genentech's antibody engineering capabilities to develop next-generation bispecific antibodies for CNS disorders[@lundbeckgenentech].
Clinical Data:
- Lu AG09222 Phase 1 completed in 2023, demonstrating safety and tolerability
- Platform has shown 5-10x increased brain exposure in preclinical models
- Multiple candidates in early clinical testing for AD and PD
Product Pipeline
| Product | Indication | Development Stage | Notes |
|---------|------------|-------------------|-------|
| Lu AF20513 | Alzheimer's disease | Phase 1 | Amyloid vaccine, brain shuttle |
| Lu AF87908 | Alzheimer's disease | Phase 1 | Tau brain shuttle bispecific |
| Lu AG09222 | Migraine | Phase 1 | PACAP38/TfR brain shuttle |
| Lu AG06466 | Parkinson's disease | Phase 1 | Alpha-synuclein modulator |
| Droxidopa (Northera) | Neurogenic orthostatic hypotension | Approved (FDA) | Acquired from NeuroMedix |
| FMR | Depression | Phase 2 | Fast-acting glutamate modulator |
| Lu AF20071 | Schizophrenia | Phase 1 | Dopamine-serotonin modulator |
Droxidopa (Northera) - Orthostatic Hypotension Treatment
Lundbeck acquired droxidopa (brand name Northera) from NeuroMedix in 2016, expanding their Parkinson's disease portfolio to include treatment for autonomic dysfunction. Droxidopa is an FDA-approved norepinephrine prodrug indicated for the treatment of symptomatic neurogenic orthostatic hypotension (nOH)[@droxidopa-fda].
Mechanism of Action:
- Droxidopa is a synthetic amino acid that is converted to norepinephrine in the body
- It works by increasing norepinephrine levels to compensate for the sympathetic nervous system dysfunction seen in PD
- Addresses the loss of postganglionic sympathetic neurons that causes orthostatic hypotension in Parkinson's disease
Clinical Profile:
- FDA Approval: 2014 (for neurogenic orthostatic hypotension)
- Indication: Treatment of orthostatic hypotension associated with Parkinson's disease, multiple system atrophy, and pure autonomic failure
- Dosing: Typically 100-600 mg, three times daily
- Key advantage: Addresses the underlying norepinephrine deficiency rather than just symptoms
Market Context:
- Neurogenic orthostatic hypotension affects 30-50% of Parkinson's disease patients
- Droxidopa is one of only three FDA-approved treatments for orthostatic hypotension
- Lundbeck markets Northera in the United States through their specialty sales force
Marketed Products
Key CNS Products
Lundbeck's commercial portfolio includes treatments for psychiatric and neurological disorders:
| Product | Indication | Mechanism |
|---------|------------|-----------|
| Cipramil/Celexa | Depression | SSRI |
| Escitalopram | Depression/anxiety | SSRI |
| Brintellix/Trintellix | Depression | Multimodal serotonin modulator |
| Abilify Maintena | Schizophrenia/bipolar | Dopamine partial agonist |
| Ongentys | Parkinson's disease Disease | COMT inhibitor |
| Aubagio | Multiple Sclerosis | Immunomodulator (licensed from Sanofi) |
Recent Commercial Updates
- Trintellix (vortioxetine): Continues to be a key growth driver in major depression
- Ongentys (opicapone): [Parkinson's disease adjunct therapy showing strong uptake
- Sanofi partnership: Distribution agreement for Aubagio expands CNS portfolio
Business Strategy
Focus Areas
Lundbeck's strategy centers on becoming a leader in specialized neuroscience:
Concentrated CNS expertise: Maintain focus on brain diseases where the company has deep expertise
External innovation: License and acquire programs to supplement internal R&D
Geographic expansion: Grow in emerging markets while maintaining developed market presence
Pipeline prioritization: Focus resources on high-value programs with clear regulatory pathwaysPartnerships
- Sanofi: Distribution agreement for Aubagio and other products
- Alzheon: Collaboration on [Alzheimer's disease therapeutics
- Otsuka: Co-development in certain psychiatric indications
Financial Overview
| Metric | 2023 | 2022 | 2021 |
|--------|------|------|------|
| Revenue (DKK) | 14.5B | 15.7B | 17.2B |
| R&D Investment | ~3.0B | ~2.9B | ~2.8B |
| Operating Margin | ~15% | ~18% | ~22% |
- [Brain Shuttle Technologies](/technologies/brain-shuttle-technologies)
- [Technologies/Brain Shuttles](/technologies/brain-shuttles)
- [Psychiatric and Neurological Disorders](/genes/atr)
External Links
- [Lundbeck Official](https://www.lundbeck.com)
References
Unknown, Lundbeck Annual Report 2023 (2023)
Unknown, Lundbeck Pipeline Overview (n.d.)
Unknown, Lundbeck Foundation (n.d.)
Unknown, Alzheon Collaboration (n.d.)
Unknown, Lundbeck Brain Shuttle Platform (2024) (2024)
Unknown, Lundbeck-Genentech Bispecific Antibody Collaboration (n.d.)